(C) Reuters. FILE PHOTO: A Walgreens store is seen in Chicago, Illinois, U.S. February 11, 2021. REUTERS/Eileen T. Meslar
(Reuters) – Walgreens Boots Alliance (NASDAQ:WBA) Inc on Thursday raised its 2021 adjusted profit growth forecast, buoyed by strength in drug sales and COVID-19 vaccine administrations.
The company, one of the largest U.S. pharmacies, had been relying on gains from administering COVID-19 vaccines to tide over losses from low prescription volumes and a weak flu season that has hampered over-the-counter sales of health and wellness products in recent quarters.
However, prescription volumes improved in the third quarter amid a drop in COVID-19 cases in the United States and easing of social-distancing protocols and lockdowns.
Walgreens said it had administered more than 25 million COVID-19 vaccinations to date out of the 326.5 million shots given in the United States as of June 30.
Same-store sales at its U.S. pharmacies rose 6.4% in the third quarter as it filled 312.1 million prescriptions.
Walgreens raised its 2021 adjusted earnings per share forecast from mid-to-high single digit growth to around 10 percent growth.
Net income attributable to the company was $1.2 billion, or $1.38 per share, for the quarter ended May 31, compared with a net loss of $1.71 billion, or $1.95 per share, a year earlier.
Walgreens raises FY profit growth forecast on strength in drug sales
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.